1. Drug Approval Process (India – CDSCO Framework)

In India, drug regulation is primarily governed by the Drugs and Cosmetics Act, 1940 and the New Drugs and Clinical Trials Rules, 2019 (NDCTR 2019), administered by the Central Drugs Standard Control Organization (CDSCO) under the Drug Controller General of India (DCGI).

(A) Discovery and Pre-Clinical Testing

Before human trials:

• Laboratory research (in vitro studies)
• Animal testing (toxicology, safety pharmacology)
• Focus: toxicity, carcinogenicity, reproductive effects

Legal requirement: Data must comply with ethical animal testing norms and OECD-like standards.

(B) Clinical Trials (Human Testing)

Phase I – Safety

• Small group (20–100 healthy volunteers)
• Tests: safety, dosage range, pharmacokinetics

Phase II – Efficacy

• 100–300 patients
• Determines whether drug works for target disease

Phase III – Large Scale Testing

• 1,000–3,000+ patients
• Confirms efficacy and monitors adverse reactions

Phase IV – Post Marketing Surveillance

• After approval
• Long-term effects, rare side effects

Legal safeguard: Mandatory Ethics Committee approval + informed consent + DCGI permission

(C) Regulatory Approval (India)

Drug manufacturer must submit:

• Clinical trial data
• Risk-benefit analysis
• Manufacturing standards (GMP compliance)
• Labeling information

DCGI evaluates:

• Safety
• Efficacy
• Quality

If satisfied → marketing authorization granted.

(D) Post-Approval Control

• Pharmacovigilance (ADR reporting)
• Drug recall power
• Ban on unsafe drugs under Section 26A of Drugs and Cosmetics Act

2. Legal Standards Governing Drug Approval

(A) Safety and Efficacy Standard

A drug must be:

• Safe (acceptable risk level)
• Effective (therapeutic benefit proven)

No drug is “zero risk”; law applies risk–benefit balancing test.

(B) Informed Consent (Ethical + Legal)

Patients in clinical trials must:

• Be informed of risks
• Voluntarily participate
• Be free from coercion

Violation leads to civil and criminal liability.

(C) Strict Regulatory Compliance

Manufacturers must comply with:

• Good Clinical Practice (GCP)
• Good Manufacturing Practice (GMP)

(D) Product Liability Principles

If harm occurs:

• Manufacturer may be liable under negligence
• In some jurisdictions, strict liability applies

3. Important Case Laws (Explained in Detail)

1. Wyeth v. Levine (U.S. Supreme Court, 2009)

Facts:

A woman received an anti-nausea drug (Phenergan) manufactured by Wyeth. The drug was administered via “IV push” method, which led to gangrene and eventual amputation. She sued the company for failure to warn.

Legal Issue:

Does FDA approval of drug labeling shield manufacturers from liability?

Judgment:

• Supreme Court held NO immunity for manufacturers
• Companies remain responsible for adequate warnings

Principle Established:

Even after regulatory approval, pharmaceutical companies must ensure:

• Proper labeling
• Adequate risk disclosure

Significance:

Strengthened product liability law over regulatory defense

2. FDA v. Brown & Williamson Tobacco Corp. (2000)

Facts:

FDA attempted to regulate tobacco products as “drug delivery devices” because nicotine affects the body.

Legal Issue:

Does FDA have authority to regulate tobacco under drug laws?

Judgment:

• Supreme Court ruled FDA does NOT have authority
• Tobacco regulation lies with Congress, not FDA interpretation

Principle:

• Regulatory bodies cannot expand jurisdiction beyond legislative intent

Significance:

Clarified limits of drug regulatory authority and statutory interpretation

3. United States v. Rutherford (1979)

Facts:

Cancer patients demanded access to “Laetrile,” an unapproved drug claimed to treat cancer.

Legal Issue:

Can terminally ill patients access unapproved drugs?

Judgment:

• Supreme Court ruled FDA approval is mandatory
• No exemption even for terminally ill patients

Principle:

• Safety and efficacy standards apply universally

Significance:

Reinforced strict regulatory control over experimental drugs

4. Abigail Alliance v. Von Eschenbach (2007)

Facts:

Terminally ill patients argued they had a constitutional right to access experimental drugs after Phase I trials.

Legal Issue:

Is there a constitutional right to access unapproved drugs?

Judgment:

• Court rejected the claim
• No fundamental right to experimental treatment

Principle:

• FDA authority overrides individual access claims

Significance:

Balanced:

• Right to life
• Regulatory protection of public safety

5. Indian Case: Vincent Panikurlangara v. Union of India (1987)

Facts:

Petitioner challenged unrestricted availability of unsafe drugs in India and demanded stronger regulation.

Issue:

Whether the government must ensure safety of drugs under constitutional duty.

Judgment:

• Supreme Court held:
  • Government has constitutional obligation under Article 21 (Right to Life) to ensure drug safety
• Directed stricter drug regulation

Principle:

Drug safety is part of the Right to Life and Public Health

Significance:

First major Indian recognition that:

• Unsafe drugs violate fundamental rights

6. Indian Case: Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd. (2001)

Facts:

Dispute over deceptively similar drug names causing prescription errors.

Issue:

Standard for drug naming and consumer confusion.

Judgment:

• Supreme Court emphasized higher standard of care for drugs
• Even minor confusion can endanger life

Principle:

• Pharmaceutical industry must maintain strict vigilance in branding and labeling

Significance:

Strengthened consumer protection in drug marketing

4. Key Legal Principles Emerging from These Cases

Across jurisdictions, courts consistently hold:

1. Public Health Supremacy

Drug regulation prioritizes population safety over individual preference.

2. No Absolute FDA/Regulatory Shield

Approval does not eliminate manufacturer liability.

3. High Standard of Care

Pharmaceutical companies owe a heightened duty of care.

4. Informed Risk Disclosure

Failure to warn = legal liability.

5. Limited Access to Experimental Drugs

Even terminal patients cannot bypass safety protocols.

5. Conclusion

The drug approval system is a multi-layered legal safeguard mechanism combining:

• Scientific validation (clinical trials)
• Regulatory control (CDSCO/FDA)
• Constitutional principles (Right to Life)
• Judicial oversight (product liability + safety enforcement)

The case law clearly shows a consistent global principle:

“Drug regulation is not only administrative—it is a constitutional and human safety obligation.”